Alector Reports Third Quarter 2023 Financial Results and Provides Business Update
November 07, 2023 16:05 ET
|
Alector, Inc.
Achieved Q4 2023 target enrollment in pivotal INFRONT-3 Phase 3 latozinemab clinical trial with 103 symptomatic FTD-GRN participants Enrollment completed in the INVOKE-2 Phase 2 clinical...
Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
October 27, 2023 07:00 ET
|
Alector, Inc.
--101 symptomatic FTD-GRN participants enrolled in INFRONT-3 -- SOUTH SAN FRANCISCO, Calif., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company...
Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease
September 07, 2023 07:00 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it has...
Alector to Participate in Upcoming Healthcare Conferences
August 31, 2023 07:00 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will...
Alector Reports Second Quarter 2023 Financial Results and Provides Business Update
August 03, 2023 16:05 ET
|
Alector, Inc.
Closed screening in the INVOKE-2 Phase 2 trial of AL002 in participants with early Alzheimer’s disease; completing enrollment in Q3 2023, with data readout expected in Q4 2024 ...
Alector to Host Mid-Year Earnings Conference Call
July 27, 2023 08:30 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it will host a...
Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
June 06, 2023 07:00 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will...
Alector Reports First Quarter 2023 Financial Results and Provides Business Update
May 04, 2023 16:05 ET
|
Alector, Inc.
On track to engage with regulatory authorities on the pivotal Phase 3 INFRONT-3 clinical trial of latozinemab in mid-2023; targeting data readout in early 2025 Plan to present additional results from...
Alector to Participate in the BofA Securities 2023 Healthcare Conference
May 02, 2023 07:00 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will...
Alector to Participate in Upcoming Healthcare Conferences
March 01, 2023 16:05 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will...